

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Tomono Kawase

Date: 15. April. 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSMO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jsco.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☒	
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Tomono Kawase

Signature: Tomono Kawase

Date: 15. April 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Hiroshi Imamura

Date: 27, Mar. 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable) _____

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902) _____

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jsco.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	✓	
2. Stock ownership	✓	
3. Patent licensing fees	✓	
4. Honoraria (e.g. lecture fees)		✓ TAIHO Pharm. CO. LTD
5. Fees for promotional materials (e.g. manuscript fee)	✓	
6. Research funding	✓	
7. Legal fees in case of lawsuit	✓	
8. Scholarship donations	✓	
9. Endowed chairs	✓	
10. Others (e.g. trips, travel, or gifts)	✓	

Printname: Hiroshi Imamura _____

Signature: Hiroshi Imamura _____

Date: 27, Mar, 2023 _____

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Ryohei Kawabata

Date: Mar 7, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jsco.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☒	
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Ryohei Kawabata

Signature: Ryohei Kawabata

Date: Mar 7 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Jin Matsuyama

Date: May 8th, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified in a separate sheet as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	✓	
2. Stock ownership	✓	
3. Patent licensing fees	✓	
4. Honoraria (e.g. lecture fees)	✓	
5. Fees for promotional materials (e.g. manuscript fee)	✓	
6. Research funding	✓	
7. Legal fees in case of lawsuit	✓	
8. Scholarship donations	✓	
9. Endowed chairs	✓	
10. Others (e.g. trips, travel, or gifts)	✓	

Printname: Jin Matsuyama

Signature: Jin Matsuyama

Date: May 8th. 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Kazuhiro Nishikawa Date: 17 Mar 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or


Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☐	☒ Bristol-Myers Squibb, Daiichi-Sankyo, EA Pharma, Eli Lilly Japan, MSD, Ono, and Taiho
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Kazuhiro Nishikawa

Signature: 

Date: 17 Mar 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature:



Date:



This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or


Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☒	
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Kazuhiro Yanagihara

Signature: 

Date: April/5/2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title: *Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)*

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Kazuyoshi Yamamoto

Date: Mar 7, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSMO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☒	
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Kazuyoshi Yamamoto

Signature: Kazuyoshi Yamamoto

Date: Mar. 7, 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: _____

Noriyuki Hoki

Date: _____

03/15, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable) _____

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902) _____

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSMD Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or


Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☒	
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Printname: Noriyuki Hoki

Signature: 

Date: Mar.15,2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Junji Kawada

Date: Mar 08, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable) _____

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902) _____

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	✓	
2. Stock ownership	✓	
3. Patent licensing fees	✓	
4. Honoraria (e.g. lecture fees)	✓	
5. Fees for promotional materials (e.g. manuscript fee)	✓	
6. Research funding	✓	
7. Legal fees in case of lawsuit	✓	
8. Scholarship donations	✓	
9. Endowed chairs	✓	
10. Others (e.g. trips, travel, or gifts)	✓	

Print name: Junji Kawada

Signature: Junji Kawada

Date: Mar, 08, 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: _____

Hisato Kawakami

Date: Mar 08, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for olde

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSMO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☐	☒ BMS K.K., ONO Pharmaceutical Co., LTD., Ei
5. Fees for promotional materials (e.g. manuscript fee)	☐	☒ ONO Pharmaceutical Co., LTD., üMSD K.K., a
6. Research funding	☐	☒ BMS K.K., Eisai Co., Ltd., and Kobayashi Phar
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Printname: Hisato Kawakami

Signature: 

Date: Mar 08, 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title: Phase II study of S-1 plus docetaxel as first line treatment for older patients with advanced gastric cancer (OGSG0902)

Authors' names:

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: S. Li S. Li

Date: 24/Apr/2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSMO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified in a separate sheet as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jsco.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☐	☒ Daichi Sankyo, Chugai
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☐	☒ Eli Lilly, Daichi Sankyo, Taiho.
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Daisuke Sakai

Signature: [Handwritten Signature]

Date: 04 / Apr / 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names: Yukinori Kurokawa

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature:

Yukinori Kurokawa

Date:

Mar 8, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jSCO.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)		☒ Taiho Pharmaceutical.
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding		☒ Taiho Pharmaceutical.
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Yukinori Kurokawa

Signature:

Yukinori Kurokawa

Date: Mar 8, 2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:

Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: Kazuhiro Nishikawa

Date: Apr. 5, 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSMO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jsco.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☒	
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☒	
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☒	
9. Endowed chairs	☒	
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: Toshio Shimokawa

Signature: Toshio Shimokawa

Date: Apr.5.2023

Prerequisites for Publication

Editorial policy

The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication. Submission of papers translated into English from articles published in another language is not allowed. Secondary publication of an article published in IJCO in a language other than English is acceptable, provided all the conditions stipulated in "Acceptable Secondary Publication" in Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org/) are met.

Ethical considerations

Papers on studies involving human subjects must be accompanied by a statement that the research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. This statement must appear in the Patients and methods section of the manuscript.

All papers reporting experiments using animals must include a statement in Materials and methods giving assurance that all animals received humane care in compliance with the guidelines of the authors' own institution or the National Research Council's criteria for humane care as outlined in *Guides for the Care and Use of Laboratory Animals* prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication no. 86-23, revised 1985).

Certification Form — to be submitted with the manuscript

International Journal of Clinical Oncology

Manuscript title:


Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Authors' names:

Tomono Kawase, Hiroshi Imamura, Ryohei Kawabata, Jin Matsuyama, Kazuhiro Nishikawa, Kazuhiro Yanagihara, Kazuyoshi Yamamoto, Noriyuki Hoki, Junji Kawada, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, and Taroh Satoh

I/We certify that the work submitted herewith is in full accordance with the editorial policy and ethical considerations set forth in the "Prerequisites for Publication" in the *International Journal of Clinical Oncology*.

I/We also agree that the copyright for my/our article will be transferred to the Japan Society of Clinical Oncology when it is accepted for publication in the *International Journal of Clinical Oncology*.

Signature: 

Date: 05 MAR 2023

This certificate must be signed by all authors. If there are more than five authors, make copies of this form as required.

International Journal of Clinical Oncology

Conflict of Interest Disclosure Statement

(Form 2)

Manuscript No. (only if applicable)

Manuscript Title: Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Each author is required to complete and return this form to the corresponding author.

When submitting a manuscript to the International Journal of Clinical Oncology, all authors are required to disclose any financial relationship with a biotechnology manufacturer, a pharmaceutical company, or other commercial entity that has an interest in the subject matter or materials discussed in the manuscript. The matters requiring disclosure are outlined in Guidelines on Conflicts of Interest in JSCO/JSO Business and Activities (Articles of Association Enforcement Bylaws No. 4).

All of the forms from each author need to be uploaded online and submitted with the manuscript at the time of submission by the corresponding author. Certify that all financial and material support for this research and work are clearly identified **in a separate sheet** as follows.

Conflict of Interest Statement

A (author name) serves as a consultant to Z (entity name); B's spouse is chairman of Y; C received a research grant from X; D received lecture fees from V; E holds a patent on U; F has been reimbursed by T for attending several conferences; G received honoraria for writing promotional material for S; H has no conflict of interest.

or


Conflict of Interest Statement

The authors declare that they have no conflict of interest.

If you, your spouse, or other immediate family member, has any of the listed relationships with a commercial entity that has an interest in the subject matter in your manuscript, please refer it to the JSCO's definition for conflict of interest which must be disclosed (<http://www.jsco.or.jp/english/index/page/id/75#bylaws4>). And then, check the appropriate "Yes" box below and provide details. If the listed relationship does not apply to you or your family member, check the appropriate "No" box.

Categories	No	Yes (Give names of authors and entities)
1. Employment/Leadership position/ Advisory role	☒	
2. Stock ownership	☒	
3. Patent licensing fees	☒	
4. Honoraria (e.g. lecture fees)	☐	☒ Ono Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical, Eli-Lilly, Bristol-Myers, MSD, Taiho Pharmaceutical
5. Fees for promotional materials (e.g. manuscript fee)	☒	
6. Research funding	☐	☒ Ono Pharmaceutical, Chugai Pharmaceutical, Eli-Lilly, Bristol-Myers, MSD, Taiho Pharmaceutical, Hutch Med
7. Legal fees in case of lawsuit	☒	
8. Scholarship donations	☐	☒ Taiho Pharmaceutical
9. Endowed chairs	☐	☒ Ono Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical
10. Others (e.g. trips, travel, or gifts)	☒	

Print name: TAROH SATOH

Signature: 

Date: 08/03/2023